Quick Summary — SEPN scores higher on quality with 6.9/10 vs SCNI's 1.9/10. SCNI trades at $0.48 while SEPN trades at $29.94. Both analyzed daily using SEC EDGAR data across 13 institutional models.
SEPN scores higher with a 6.9/10 quality rating vs SCNI's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $0.48, SCNI trades +74.0% above its Bayesian DCF fair value of $0.12, while SEPN at $29.94 trades +48.8% above its estimate of $15.33. SCNI shows a wider gap between price and intrinsic value.
SCNI earns a Quality of Company score of 1.9/10 compared to SEPN's 6.9/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
SCNI carries a SAFE value trap risk (12/100) while SEPN shows SAFE risk (12/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both SCNI and SEPN operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare SCNI vs SEPN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.